As earnings season is upon us, we’re receiving a clearer view of what new medtech could be launching this year in the medical device space. Companies still feel hamstrung by macroeconomic pressures, supply chain issues and more. However, many pointed out that 2023 has plenty to look forward to. Several quarterly reports and earnings calls […]
Edwards Lifesciences
5 reasons you should feel good about medtech companies in 2023
“Macroeconomic headwinds” is a phrase repeated a lot these days, but a string of positive medtech company earnings reports this week should cheer medical device industry insiders. The medical device industry may once again prove that it’s an economically resilient space. “While 2022 brought its share of supply chain and inflationary pressures, directionally, many companies […]
Edwards stock up on Street-beating Q4
Edwards Lifesciences (NYSE:EW) stock is up today — a day after the company announced fourth-quarter results that beat the consensus forecast. Shares of EW were up more than 3% at $79.63 apiece by late morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day […]
The biggest medtech stock gainers, losers in 2022
In another roller coaster year for medtech, these are the companies that saw their stock rise and fall the most drastically. The MassDevice MedTech 100 Index, which includes stocks of the world’s largest medical device companies, reflects the performance of many in the medtech space. In a tough year for a lot of businesses, the Index […]
The top 10 cardiac device stories of 2022
From pulsed-field ablation to noninvasive monitoring, this was an exciting year for cardiac device tech. Here are the top 10 cardiac device stories from MassDevice and its sister sites: 10. Medtronic to pay Acutus $17M following EU MDR submission of left-heart access portfolio Earlier this year, Acutus agreed to sell its left-heart access portfolio to […]
Edwards Lifesciences CEO to step down next year
Edwards Lifesciences (NYSE:EW) announced today that Michael A. Mussallem, chair and CEO, intends to retire next year. Mussallem, 70, informed the board of his decision to retire in connection with Edwards’ annual meeting of stockholders on May 11, 2023. At that meeting, Mussallem intends to stand for election as non-executive chair of the Edwards Board. […]
Edwards announces positive results for Evoque valve replacement system
Edwards Lifesciences (NYSE:EW) announced that one-year results from the TRISCEND study demonstrated favorable outcomes. TRISCEND, a single-arm, prospective, global, multi-center study, evaluates the Edwards Evoque system. Evoque, a transcatheter tricuspid valve replacement system, demonstrated favorable safety, efficacy and quality-of-life outcomes. Edwards presented data during the late-breaking trials session at PCR London Valves 2022. Patients enrolled […]
Edwards triggers $750M share repurchase program
Edwards Lifesciences (NYSE:EW) announced today that it executed an accelerated share repurchase agreement (ASR) worth $750 million. Irvine, California-based Edwards’ ASR consists of the repurchasing of its common stock. With the transaction, Edwards repurchased more than $1.7 billion in its own shares in 2022. Under the ASR terms, the company received an initial delivery of […]
Edwards Lifesciences misses in Q3 amid economic challenges
Edwards Lifesciences (NYSE: EW) shares are down today — a day after reporting third-quarter results that missed the Wall Street consensus forecast. EW shares were down more than 18% to $70.49 apiece by the afternoon today. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down more […]
4 major cardiology trends you need to know from TCT 2022
Medtronic, Edwards and Abbott presented positive data as TAVR, TEER and renal denervation innovations continue to arrive. The 34th Transcatheter Cardiovascular Therapeutics (TCT) conference took place in Boston this past week and a ton of big names made waves with their technologies and innovations. Medtronic, Abbott, Edwards and Boston Scientific represent a few of the […]
Edwards TEER therapy proves safe and effective in head-to-head trial with Abbott MitraClip
Edwards Lifesciences (NYSE:EW) announced data confirming its transcatheter edge-to-edge repair (TEER) as safe and effective. CLASP IID compared Edwards’ Pascal system and Abbott’s MitraClip system. The study determined that the two contemporary TEER therapies are safe and effective in patients with degenerative mitral regurgitation (DMR). Results from the trial were presented at the 34th Transcatheter […]